Acquired haemophilia in association with type III von Willebrand's disease: successful treatment with high purity von Willebrand's factor and recombinant factor VIIa.
A patient with autosomal dominant (Type III) von Willebrand's disease (vWd) developed acquired haemophilia post-operatively, possibly due to exposure to amoxycillin. She refused porcine factor VIII (pFVIII) on religious grounds and was managed successfully with recombinant activated factor VII (rFVIIa) together with highly purified von Willebrand factor concentrate (vWf-VHP). In patients with acquired haemophilia rFVIIa appears to be a suitable agent for symptomatic management.
Majumdar
G
G
Haemophilia Reference Centre, St Thomas' Hospital, London, UK.
Phillips
J K
JK
Lavallee
H
H
Savidge
G F
GF
D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005799:Genes, Dominant; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D014842:von Willebrand Diseases / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D014841:von Willebrand Factor / Q000302:isolation & purification / Q000627:therapeutic use*
D011994:Recombinant Proteins; D014841:von Willebrand Factor; D015942:Factor VIIa